The group treated with oral finasteride demonstrated 109%, 96.0%, 115%, and 9.93% higher expression levels of ALDH1, β-catenin, cyclin D1, and PKM2, respectively, as compared to the androgenic alopecia control, as well as 7.44%, 22.9%, and 4.8% greater expression of ALDH1, β-catenin, and cyclin D1, respectively, as compared to the 1% minoxidil solution-treated group (Figure 8 and Figure S1). The gene discussed is CCND1; the disease is androgenetic alopecia.